Stacey Deleria Finley, PhD

Title(s)Associate Professor of Biomedical Engineering
SchoolViterbi School of Engineering, BME
Phone+1 213 740 8788
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    2016Keystone Symposia Fellow
    Diverse: Issues in Higher Education2015Emerging Scholar Award
    National Academy of Engineering2014Frontiers in Engineering Education
    University of Southern California2013WiSE Gabilan Assistant Professorship
    Journal Biotechnology and Bioengineering2010Elmer Gaden Jr. Award
    National Institutes of Health2010Ruth L. Kirschstein NRSA Postdoctoral Fellowship
    UNCF/Merck Science Initiative2010Postdoctoral Science Research Fellowship
    National Science Foundation2006Graduate Research Fellowship

    Collapse Overview 
    Collapse Overview
    Dr. Stacey Finley joined the Biomedical Engineering Department at USC in 2013. Dr. Finley received her Bachelor's degree in Chemical Engineering from Florida A & M University in 2004. She pursued graduate studies in Chemical Engineering and received her Ph.D. in 2009 from Northwestern University. While at Northwestern, Dr. Finley was a recipient of the NSF Graduate Research Fellowship and a participant in the NIH Biotechnology Predoctoral Training Program. Following her graduate work, Dr. Finley was a postdoctoral research fellow at Johns Hopkins University School of Medicine. She was awarded postdoctoral fellowships from the NIH National Research Service Award (NRSA) and the UNCF/Merck Science Initiative. She is a member of American Association of Cancer Research (AACR), American Institute of Chemical Engineers (AIChE), Biomedical Engineering Society (BMES), International Society for Computational Biology (ISCB), and the Society of Mathematical Biology (SMB).

    Collapse Research 
    Collapse Research Activities and Funding
    Multiscale systems biology modeling to exploit tumor-stromal metabolic crosstalk in colorectal cancer
    NIH/NCI U01CA232137Sep 13, 2018 - Aug 31, 2023
    Role: Principal Investigator
    Predictive model of pro- and anti-angiogenic factors involved in breast cancer
    NIH/NCI F32CA154213Sep 15, 2010 - Feb 14, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Twitter
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Rohrs JA, Wang P, Finley SD. Understanding the Dynamics of T-Cell Activation in Health and Disease Through the Lens of Computational Modeling. JCO Clin Cancer Inform. 2019 01; 3:1-8. PMID: 30689404.
      View in: PubMed
    2. Song M, Finley SD. Mechanistic insight into activation of MAPK signaling by pro-angiogenic factors. BMC Syst Biol. 2018 Dec 27; 12(1):145. PMID: 30591051.
      View in: PubMed
    3. Rohrs JA, Zheng D, Graham NA, Wang P, Finley SD. Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics. Biophys J. 2018 Sep 18; 115(6):1116-1129. PMID: 30197180.
      View in: PubMed
    4. Wu Q, Arnheim AD, Finley SD. In silico mouse study identifies tumour growth kinetics as biomarkers for the outcome of anti-angiogenic treatment. J R Soc Interface. 2018 Aug; 15(145). PMID: 30135261.
      View in: PubMed
    5. Li D, Finley SD. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment. Integr Biol (Camb). 2018 04 23; 10(4):253-269. PMID: 29623971.
      View in: PubMed
    6. Gaddy TD, Wu Q, Arnheim AD, Finley SD. Mechanistic modeling quantifies the influence of tumor growth kinetics on the response to anti-angiogenic treatment. PLoS Comput Biol. 2017 12; 13(12):e1005874. PMID: 29267273.
      View in: PubMed
    7. Wu Q, Finley SD. Predictive model identifies strategies to enhance TSP1-mediated apoptosis signaling. Cell Commun Signal. 2017 Dec 19; 15(1):53. PMID: 29258506.
      View in: PubMed
    8. Roy M, Finley SD. Computational Model Predicts the Effects of Targeting Cellular Metabolism in Pancreatic Cancer. Front Physiol. 2017; 8:217. PMID: 28446878.
      View in: PubMed
    9. Typpo KV, Wong HR, Finley SD, Daniels RC, Seely AJ, Lacroix J. Monitoring Severity of Multiple Organ Dysfunction Syndrome: New Technologies. Pediatr Crit Care Med. 2017 Mar; 18(3_suppl Suppl 1):S24-S31. PMID: 28248831.
      View in: PubMed
    10. Chu LH, Ganta VC, Choi MH, Chen G, Finley SD, Annex BH, Popel AS. A multiscale computational model predicts distribution of anti-angiogenic isoform VEGF165b in peripheral arterial disease in human and mouse. Sci Rep. 2016 11 17; 6:37030. PMID: 27853189.
      View in: PubMed
    11. Rohrs JA, Sulistio CD, Finley SD. Predictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissue. NPJ Syst Biol Appl. 2016; 2. PMID: 28713587.
      View in: PubMed
    12. Rohrs JA, Wang P, Finley SD. Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation. Cell Mol Bioeng. 2016; 9:351-367. PMID: 27547268.
      View in: PubMed
    13. Soto-Ortiz L, Finley SD. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J Theor Biol. 2016 Apr 07; 394:197-211. PMID: 26826488.
      View in: PubMed
    14. Finley SD, Chu LH, Popel AS. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today. 2015 Feb; 20(2):187-97. PMID: 25286370; PMCID: PMC4336587.
    15. Logsdon EA, Finley SD, Popel AS, Mac Gabhann F. A systems biology view of blood vessel growth and remodelling. J Cell Mol Med. 2014 Aug; 18(8):1491-508. PMID: 24237862; PMCID: PMC4190897.
    16. Finley SD, Dhar M, Popel AS. Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice. Front Oncol. 2013; 3:196. PMID: 23908970; PMCID: PMC3727077.
    17. Finley SD, Popel AS. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst. 2013 Jun 05; 105(11):802-11. PMID: 23670728; PMCID: PMC3672077.
    18. Finley SD, Popel AS. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J. 2012 Sep; 14(3):500-9. PMID: 22547351; PMCID: PMC3385824.
    19. Finley SD, Engel-Stefanini MO, Imoukhuede PI, Popel AS. Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies. BMC Syst Biol. 2011 Nov 21; 5:193. PMID: 22104283; PMCID: PMC3229549.
    20. Yen P, Finley SD, Engel-Stefanini MO, Popel AS. A two-compartment model of VEGF distribution in the mouse. PLoS One. 2011; 6(11):e27514. PMID: 22087332; PMCID: PMC3210788.
    21. Klinke DJ, Finley SD. Timescale analysis of rule-based biochemical reaction networks. Biotechnol Prog. 2012 Jan-Feb; 28(1):33-44. PMID: 21954150; PMCID: PMC3381993.
    22. Finley SD, Gupta D, Cheng N, Klinke DJ. Inferring relevant control mechanisms for interleukin-12 signaling in naïve CD4+ T cells. Immunol Cell Biol. 2011 Jan; 89(1):100-10. PMID: 20479776.
      View in: PubMed
    23. Finley SD, Broadbelt LJ, Hatzimanikatis V. In silico feasibility of novel biodegradation pathways for 1,2,4-trichlorobenzene. BMC Syst Biol. 2010 Feb 02; 4:7. PMID: 20122273; PMCID: PMC2830930.
    24. Finley SD, Broadbelt LJ, Hatzimanikatis V. Computational framework for predictive biodegradation. Biotechnol Bioeng. 2009 Dec 15; 104(6):1086-97. PMID: 19650084; PMCID: PMC4073782.
    25. Finley SD, Broadbelt LJ, Hatzimanikatis V. Thermodynamic analysis of biodegradation pathways. Biotechnol Bioeng. 2009 Jun 15; 103(3):532-41. PMID: 19288443; PMCID: PMC4073797.